Loading...
•
Dec 31, 2022
Abeona Therapeutics Q4 2022 Earnings Report
Abeona Therapeutics reported financial results for the full year of 2022 and provided a corporate update.
Key Takeaways
Abeona Therapeutics reported a cash, cash equivalents, restricted cash and short-term investments totaling $52.5 million as of December 31, 2022. They anticipate submitting the BLA for EB-101 to the FDA in late 2Q/early 3Q 2023.
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022
Advancing AAV-based gene therapy candidates toward IND studies in Stargardt Disease, X-linked Retinoschisis, and Autosomal Dominant Optic Atrophy
Strengthened senior management team with executive appointments and promotions
Cash, cash equivalents, restricted cash and short-term investments totaled $52.5 million as of December 31, 2022
Forward Guidance
Abeona estimates that its current cash and cash equivalents, restricted cash and short-term investments are sufficient resources to fund operations into the third quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...